Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery.

[1]  Eric M. Reyes,et al.  Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. , 2012, American heart journal.

[2]  R. Califf,et al.  Relationship Between Vein Graft Failure and Subsequent Clinical Outcomes After Coronary Artery Bypass Surgery , 2012, Circulation.

[3]  T. Huber.  Temporal Onset, Risk Factors, and Outcomes Associated With Stroke After Coronary Artery Bypass Grafting , 2011 .

[4]  A. V. van Zundert,et al.  Peripheral vascular disease as a predictor of survival after coronary artery bypass grafting: comparison with a matched general population. , 2010, The Annals of thoracic surgery.

[5]  Sean M. O'Brien,et al.  The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. , 2009, The Annals of thoracic surgery.

[6]  J. Gummert,et al.  EuroSCORE overestimates the risk of cardiac surgery: results from the national registry of the German Society of Thoracic and Cardiovascular Surgery , 2009, Clinical Research in Cardiology.

[7]  R. Arora,et al.  Coronary vein graft disease: pathogenesis and prevention. , 2009, The Canadian journal of cardiology.

[8]  J. Coselli,et al.  The impact of peripheral vascular disease on long-term survival after coronary artery bypass graft surgery. , 2008, The Annals of thoracic surgery.

[9]  Prevent Iv Investigators.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005 .

[10]  Robert M Califf,et al.  The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. , 2005, American heart journal.

[11]  R. Califf,et al.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005, JAMA.

[12]  D. Malenka,et al.  Survival in patients with peripheral vascular disease after percutaneous coronary intervention and coronary artery bypass graft surgery. , 2004, The Annals of thoracic surgery.

[13]  I. König,et al.  Sample Size Calculations for Controlled Clinical Trials Using Generalized Estimating Equations (GEE) , 2004, Methods of Information in Medicine.

[14]  S. Lemeshow,et al.  European system for cardiac operative risk evaluation (EuroSCORE). , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  S. Nashef,et al.  Eurp-pean system for cardiac operative risk evaluation (Euro SCORE) , 1999 .

[16]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[17]  M. A. Sellers,et al.  Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). , 1998, The American journal of cardiology.

[18]  Mark F. Newman,et al.  Adverse Cerebral Outcomes after Coronary Bypass Surgery , 1996 .

[19]  L. Svensson,et al.  Screening carotid ultrasonography and risk factors for stroke in coronary artery surgery patients. , 1996, The Annals of thoracic surgery.

[20]  M. Kanchuger,et al.  Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. , 1996, The New England journal of medicine.

[21]  T Sandor,et al.  Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. , 1992, The American journal of cardiology.